TriangleDISEASE & TREATMENT SETTING
Nasopharyngeal Carcinoma
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Nasopharyngeal Carcinoma
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Derived from NCI topic(s): Nasopharyngeal Carcinoma. Strongest NCIt resolution: exact. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
7 more-specific settings
LOQTORZI: metastatic Nasopharyngeal carcinoma (first-line) →Penpulimab kcqx: metastatic Nasopharyngeal carcinoma (first-line) →Penpulimab kcqx: metastatic Nasopharyngeal carcinoma after prior therapy →Stage I Nasopharyngeal Carcinoma →recurrent Nasopharyngeal Carcinoma →Stage II Nasopharyngeal Carcinoma →Stage IVB recurrent Nasopharyngeal Carcinoma →
Study evidence for this setting
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
Stereotactic Body Radiotherapy for Head and Neck Tumors
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
Indication-specific source history
2025-04-23 · penpulimab-kcqx · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-nasopharyngeal-carcinoma
- event id
- notice-4ef2ac61108c512f
- event date
- 2025-04-23
- event kind
- approval-notification
- drug or regimen
- penpulimab-kcqx
- source indication text
- FDA approved penpulimab-kcqx with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma . FDA also approved penpulimab-kcqx as a single agent for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
- match phrase
- nasopharyngeal carcinoma
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-e43d505c8aaeb35e
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-nasopharyngeal-carcinoma
- binding id
- ncit-C3871
- source collection
- ncit-concept
- source key
- C3871
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice